Abstract |
Individual variations in glucuronation may result in differences in serum concentrations of atazanavir, resulting in lipodystrophy, illustrating the difficulty in adjusting dosage. We report the case of an HIV/HCV co-infected patient treated with atazanavir.
|
Authors | P Dellamonica |
Journal | The Journal of infection
(J Infect)
Vol. 52
Issue 6
Pg. e189-90
(Jun 2006)
ISSN: 1532-2742 [Electronic] England |
PMID | 16239035
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Oligopeptides
- Protease Inhibitors
- Pyridines
- Atazanavir Sulfate
- Bilirubin
|
Topics |
- Aged
- Atazanavir Sulfate
- Bilirubin
(blood)
- Female
- HIV Infections
(drug therapy)
- HIV-Associated Lipodystrophy Syndrome
(chemically induced)
- Hepatitis C
(drug therapy)
- Humans
- Oligopeptides
(adverse effects, blood, therapeutic use)
- Protease Inhibitors
(adverse effects, therapeutic use)
- Pyridines
(adverse effects, blood, therapeutic use)
|